
Conference Coverage
about 16 hours ago
Oral Olorofim Noninferior to AmBisome in Phase 3 OASIS Trialabout 18 hours ago
Aztreonam-Avibactam Holds Activity as MBL-Producing CRE Rise in USabout 20 hours ago
Bictegravir/Lenacapavir Well Tolerated in HIV With Comorbiditiesabout 21 hours ago
Household Contacts Drive Most Hepatitis B Exposures in Young Childrenabout 22 hours ago
Isavuconazole Has Lowest Hepatotoxicity Signal Among Azoles in FAERSLatest Content

Shorts










Videos
Contagion Digital Edition









All News

Isavuconazole had a lower liver adverse event signal than voriconazole and posaconazole, while olorofim, manogepix, and rezafungin held activity against resistant molds.

Data being presented at IDWeek 2026 show zoliflodacin maintains high gonorrhea cure rates in patients co-infected with chlamydia. David Altarac, MD, discusses the therapy and the study being presented at the conference.

In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.

Oral pritelivir improved lesion healing and cut hospitalizations from 76% to 29.4% vs investigator's choice therapy in immunocompromised patients with refractory HSV.

Investigational cefiderocol-xeruborbactam inhibited 98.5% of carbapenem-nonsusceptible Acinetobacter and nearly all Enterobacterales in global surveillance data.

Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.

The FDA approved bepirovirsen (Hibsago; GSK) with nucleos(t)ide analogue therapy for chronic hepatitis B, based on B-Well 1 and 2 functional cure rates of 19% vs 0% with placebo.

In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.

The first animal model of neonatal sepsis to evaluate protection by maternal vaccination evidences transfer of immunity against virulent, often antibiotic-resistant Klebseilla pneumoniae.

The CHMP adopted a positive opinion on an extension of indication for AstraZeneca's H5N1 pandemic influenza vaccine at its October meeting.

The company, Family Farmstead Dairy, issued a raw cheddar recall over potential contamination with Shiga toxin-producing Escherichia coli (STEC) is happening across 7 states.

The guidelines issued by the Department of Health and Human Services (HHS) have been updated with recent, evidence-based consensus of The Panel for the Use of Antiretroviral Agents in Adults and Adolescents.

As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.

As of October 15, CDC reports 9235 confirmed cases and 4444 deaths in the Bundibugyo virus Ebola outbreak in the DRC, now the second-largest on record.

The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.


























































































































































































